Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing connective tissue diseases (CTD) and other autoimmune conditions. AVISE CTD provides clinicians with critical information to accurately diagnose autoimmune and connective tissue diseases. Traditional screening methods ...